Flow Analysis Cash and cash equivalents at the end of H1 2019 decreased by 6mTHB from the start of the period to 33mTHB. The main differences on a year-on-year comparison is the increase in operational
long run; and (3) To help create the opportunity to increase the Company’s share price and dividend from its operational results in the future. 7. Source of Funds The Company will utilize the proceeds
the increase of liabilities from Bill of Exchange of 535 million Baht. The main liabilities include short-term loans from financial institutions of 2,771 million Baht, current portion of long- term
that will support continuous growth momentum in demand for medical devices in Thailand. In 2019, the Company has improved and increased the sales team to increase sales efficiency in distributor of
share. 8. Sources of Financing The Company will finance this Transaction with the capital received from the capital increase of the Company of Baht 9.90 million. As of 31 December 2019, the Company has
finance this Transaction with the capital received from the capital increase of the Company of Baht 9.90 million. As of 31 December 2019, the Company has cash and cash equivalent as well as current
, an increase of 121 million baht or 9% y-y. The Company reported net profit attributed to owners of the parent of 1,184 million baht, an increase of 128 million baht or 12% y-y and 17% q-q, and earning
; (6) asset value of mutual fund; (7) issuance of investment units and an increase or reduction of registered capital whereby there shall be a requirement specifying that the management company shall
subsidiaries financial statement for the fiscal year 2014, ended as of December 31, 2014 (Revised Version) which details are as following; Result 2014 (Revised Version) 2013 Increase (Decrease) Million Baht